Nimodipine (GTx-104)

Small molecule

CRLnot approved

Evidence outlook · regulatory review

Subarachnoid Hemorrhage: FDA issued a complete response letter (2026-04-23)

FDA issues complete response letter for the GTx-104 NDA. A complete response letter means the application was not approved as filed; the sponsor may resubmit. The event is listed under Regulatory events.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Subarachnoid Hemorrhage
NCT05995405 · Grace Therapeutics Inc.
2023-10-20 – 2024-12 · Aneurysmal Subarachnoid Hemorrhage (aSAH)
What this study did
Phase 1 (1)
Subarachnoid Hemorrhage
NCT05418348 · Grace Therapeutics Inc.
2021-08-26 – 2022-02-24 · Aneurysmal Subarachnoid Hemorrhage
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Subarachnoid Hemorrhage: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Nimodipine (GTx-104): this drugPhase 3Small moleculeL-type calcium channels (Cav1.2)not yet gradedNo reviewed efficacy summary in this indication
Nimodipine (Nimotop)
ApprovedUS marketing discontinued
Small moleculeL-type calcium channels (Cav1.2)not yet gradedNo reviewed efficacy summary in this indication
Lercanidipine
—(overall)
Small moleculeL-type calcium channels (Cav1.2)
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 April 2026Complete response letterFDA issues complete response letter for the GTx-104 NDA
US, FDA · Grace Therapeutics · Source ↗